SEC Filing Summary: SIGA Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SIGA Technologies, Inc. on March 21, 2013. The filing reports the election of a new director to fill an existing vacancy on the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Jeffrey B. Kindler as a director. Upon appointment, Mr. Kindler was granted stock options to acquire 25,000 shares of common stock at an exercise price of $3.89 per share. These options vested immediately on the date of the grant.
Management Commentary and Risks
The filing highlights Mr. Kindler's extensive experience in the pharmaceutical industry, including his former role as Chairman and CEO of Pfizer. No specific risks, contingencies, or unusual items were disclosed in this filing. The document does not contain forward-looking guidance or management commentary regarding future financial performance.
Key Facts for Investor Verification
- Jeffrey B. Kindler was elected to the Board of Directors on March 21, 2013.
- Mr. Kindler received 25,000 fully vested stock options with an exercise price of $3.89.
- The filing does not disclose any financial results or changes in the company's operational status.
- Mr. Kindler brings prior executive experience from Pfizer, McDonald's, and General Electric.